Allergy Therapeutics plc (LON:AGY – Get Free Report) shares hit a new 52-week low during trading on Tuesday. The stock traded as low as GBX 1.10 and last traded at GBX 1.60, with a volume of 12,445,216 shares traded. The stock had previously closed at GBX 3.50.
Allergy Therapeutics Stock Down 54.3%
The business’s 50 day simple moving average is GBX 4.86 and its 200-day simple moving average is GBX 8.06. The company has a market cap of £101.32 million, a price-to-earnings ratio of -1.65, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
